omniture

Which is the Real Terminator of H1N1 Disease, the Antisepsis or the Vaccine?

2009-09-01 20:24 1834

SHANGHAI, Sept. 1 /PRNewswire-Asia/ -- Linkwell Corporation (OTC Bulletin Board: LWLL), a leading developer, manufacturer and distributor of healthcare-related disinfectants in China, put forward its worries about the trend of the misunderstanding concerning dealing with the spread of H1N1.

"Antisepsis is one of the most effective measures to prevent and control infectious diseases, and it will work best when used with the H1N1 vaccine," said Xuelian Bian, the Chairman and CEO of Linkwell Corporation, concerning the increasingly severe worldwide outbreak of H1N1 influenza. "Nearly all countries are making H1N1 vaccine production a top priority, which will bring some certain potential risks. With several years of experience in epidemiological research and infectious diseases in the Second Military Medical University, I am well aware of the current vaccine developments and production speed cannot keep up with the rate of virus mutation. In fact, the most economical and effective way to prevent the virus is to disinfect the breeding ground for pathogens, cutting off their routes of transmission by strengthening the personal hygiene, disinfection and isolation protection of susceptible people. The Chinese Ministry of Health has attached increasingly great importance to disinfection in medical institutions in recent years. At present, it is the Chinese masses that need to be educated about disinfection, so that more people know how to use antisepsis and health care products correctly."

Mr. Bian also commented, "To confront H1N1 influenza, Linkwell's 90%-held subsidiary, Likang Company, as a professional disinfectant supplier, contributes actively and responsibly. In the first half of this year, bottled disinfectants sent to most of hospitals around the country increased by tens of thousands, owing to the H1N1 disease. Due to last year's Wenchuan Earthquake in China, Likang was ordered by China's Ministry of Health to provide to the disaster areas a large amount of disinfectant, of which more than 400 tons were transported by air due to urgent need.

"We are carrying out R&D on new types of disinfectant to combat the influenza virus," Chairman Xuelian Bian emphasized, "Over the past few years, Likang has focused on the medical disinfection market in China, rejecting offers of cooperation from institutional investors who have wanted to invest in the civilian public health market many times. Nevertheless, the situation of the outbreak of infectious diseases throughout the world is becoming more urgent. China's 1.3 billion people make up a more than 30 billion market shares in the huge market of infection control. To Likang company, which holds a large number of civilian disinfection product technology patents, the decision to penetrate the civil disinfection market and other related markets will not only provide the most professional products and services to the whole community, but also lead to rapid growth and expansion for the company."

About Linkwell Corporation

Linkwell Corporation, through its 90% ownership of its subsidiary, Shanghai Likang Disinfectant Hi-tech Co., Ltd, develops, manufactures and distributes disinfectant healthcare products in China. Founded in 1998, Shanghai Likang Disinfectant Hi-tech Co., Ltd, has developed into China's top-ranked medical disinfection high-tech enterprise with several years' rapid growth. Formerly a Second Military Medical University-owned technology company, Likang always attaches great importance to the R&D and sales of new sterilization products. The company has obtained most disinfection product licenses approved by the Ministry of Health, and is equipped with the all the liquid, gel, powder and tablet production lines. The company is in possession of 12 patents and has 25 others in process, as well as a great deal of

know-how. The company can put forward two to four new products each year. Being the largest provider of medical disinfection products and technical service providers, Linkwell has a national marketing and sales presence in more than 5,000 medical institutions, throughout all 22 provinces, five autonomous regions, and four special municipalities of China. For more information, please visit http://www.linkwell.us .

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations or beliefs, including, but not limited to, statements concerning the Company's operations, financial performance and condition. For this purpose, statements that are not statements of historical fact may be deemed to be forward-looking statements. The Company cautions that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, but not limited to, the impact of competitive products; pricing and new technology; changes in consumer preferences and tastes; effectiveness of marketing; changes in laws and regulations; fluctuations in costs of production; and other factors as those discussed in the Company's reports filed with the Securities and Exchange Commission from time to time. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Source: Linkwell Corporation
Related Stocks:
OTC:LWLL
collection